Proton Pump Inhibitors and Primary Liver Cancer

Main Article Content

Helge Waldum

Abstract

During the last years proton pump inhibitors (PPIs), previously regarded as very safe drugs and allowed to be sold over the counter, have been reported to give side effects in many organ systems. However, most of these negative reports probably are due to residual confounding factors. In general, the side effects of PPIs are due to their biological effect in removing the biological effect of gastric juice that is killing microorganisms, and the secondary hypergastrinemia in an unsuccessful attempt to restore normal gastric acidity. Whereas the possibility that hypergastrinemia could predispose to gastric cancer has been permanently on the agenda since the introduction of PPIs, the removal of the important protective effect towards microbes has surprisingly only been focused on during the later years as a consequence of increased interest on the gut microbiome. PPI treatment affects the microbiome, and it exists one report describing increased risk of primary liver cancer due to PPI use. Changes in the gut microbiome have been shown to participate in the pathogenesis of chronic liver diseases caused by ethanol as well as obesity. In general, chronic liver diseases predispose to liver cancer. There are also rodent studies incriminating inhibition of gastric acid secretion in the pathogenesis of primary liver cancer. However, it must be concluded that presently the role of PPIs in the development of primary liver cancer seems weak.

Article Details

How to Cite
WALDUM, Helge. Proton Pump Inhibitors and Primary Liver Cancer. Medical Research Archives, [S.l.], v. 9, n. 3, mar. 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2364>. Date accessed: 11 apr. 2021. doi: https://doi.org/10.18103/mra.v9i3.2364.
Section
Research Articles

References

1. Lassalle M, Le Tri T, Bardou M, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76(3):449-57 doi: 10.1007/s00228-019-02810-1[published Online First: Epub Date]|.
2. Smallwood RA, Berlin RG, Castagnoli N, et al. Safety of acid-suppressing drugs. Digestive diseases and sciences 1995;40(2 Suppl):63s-80s doi: 10.1007/bf02214872[published Online First: Epub Date]|.
3. Sehested TSG, Gerds TA, Fosbøl EL, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med 2018;283(3):268-81 doi: 10.1111/joim.12698[published Online First: Epub Date]|.
4. Klatte DCF, Gasparini A, Xu H, et al. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology 2017;153(3):702-10 doi: 10.1053/j.gastro.2017.05.046[published Online First: Epub Date]|.
5. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986;35 Suppl 1:42-55 doi: 10.1159/000199381[published Online First: Epub Date]|.
6. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic & clinical pharmacology & toxicology 2005;96(2):94-102 doi: 10.1111/j.1742-7843.2005.pto960202.x[published Online First: Epub Date]|.
7. Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature communications 2020;11(1):362 doi: 10.1038/s41467-019-14177-z[published Online First: Epub Date]|.
8. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016;65(5):749-56 doi: 10.1136/gutjnl-2015-310861[published Online First: Epub Date]|.
9. Tran KT, McMenamin UC, Hicks B, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Alimentary pharmacology & therapeutics 2018;48(1):55-64 doi: 10.1111/apt.14796[published Online First: Epub Date]|.
10. Waldum HL. Editorial: proton pump inhibitors (PPIs) and primary liver cancer. Alimentary pharmacology & therapeutics 2018;48(3):380-81 doi: 10.1111/apt.14841[published Online First: Epub Date]|.
11. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2010;31(4):461-76 doi: 10.1111/j.1365-2036.2009.04200.x[published Online First: Epub Date]|.
12. Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World journal of gastroenterology 2019;25(5):521-38 doi: 10.3748/wjg.v25.i5.521[published Online First: Epub Date]|.
13. Boxall EH, Sira J, Standish RA, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 2004;89(5):F456-60 doi: 10.1136/adc.2002.009837[published Online First: Epub Date]|.
14. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2020 doi: 10.1002/hep.31288[published Online First: Epub Date]|.
15. Skinner C, Thompson AJ, Thursz MR, Marchesi JR, Vergis N. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therapeutic advances in gastroenterology 2020;13:1756284820942616 doi: 10.1177/1756284820942616[published Online First: Epub Date]|.
16. Luther J, Garber JJ, Khalili H, et al. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol 2015;1(2):222-32 doi: 10.1016/j.jcmgh.2015.01.001[published Online First: Epub Date]|.
17. Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159(3):849-63 doi: 10.1053/j.gastro.2020.04.077[published Online First: Epub Date]|.
18. Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Digestive diseases and sciences 2010;55(5):1465-71 doi: 10.1007/s10620-009-0870-9[published Online First: Epub Date]|.
19. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011;54(2):562-72 doi: 10.1002/hep.24423[published Online First: Epub Date]|.
20. Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14(9):527-39 doi: 10.1038/nrgastro.2017.72[published Online First: Epub Date]|.
21. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015;148(1):30-6 doi: 10.1053/j.gastro.2014.10.042[published Online First: Epub Date]|.
22. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108(1):218-24 doi: 10.1016/0016-5085(95)90027-6[published Online First: Epub Date]|.
23. Isayama F, Hines IN, Kremer M, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. American journal of physiology. Gastrointestinal and liver physiology 2006;290(6):G1318-28 doi: 10.1152/ajpgi.00405.2005[published Online First: Epub Date]|.
24. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21(4):504-16 doi: 10.1016/j.ccr.2012.02.007[published Online First: Epub Date]|.
25. Lee JK, Merchant SA, Schneider JL, et al. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. The American journal of gastroenterology 2020;115(5):706-15 doi: 10.14309/ajg.0000000000000591[published Online First: Epub Date]|.
26. Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. Journal of cancer research and clinical oncology 2020;146(10):2693-97 doi: 10.1007/s00432-020-03261-3[published Online First: Epub Date]|.
27. Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012;10(4):422-7 doi: 10.1016/j.cgh.2011.11.019[published Online First: Epub Date]|.
28. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut 2016;65(5):740-8 doi: 10.1136/gutjnl-2015-310376[published Online First: Epub Date]|.
29. Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clinical and translational gastroenterology 2019;10(10):e00078 doi: 10.14309/ctg.0000000000000078[published Online First: Epub Date]|.
30. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 2013;11(5):483-90 doi: 10.1016/j.cgh.2012.12.011[published Online First: Epub Date]|.
31. Llorente C, Jepsen P, Inamine T, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nature communications 2017;8(1):837 doi: 10.1038/s41467-017-00796-x[published Online First: Epub Date]|.
32. Hakanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regulatory peptides 1986;13(3-4):225-33

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.